Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation

Journal of Controlled Release

Volumn 147, Issue 3, 2010, Pages 400-407

  Takahashi, Hironobu ^a,c   Wang, Yuwei ^a   Grainger, David W ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b University of Utah   (United States)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Fibrosis; Fibrous capsule; Foreign body reaction; Implant; Local delivery; MTOR siRNA

Indexed keywords

FIBROSIS; FIBROUS CAPSULE; FOREIGN BODY REACTIONS; IMPLANT; LOCAL DELIVERY; MTOR SIRNA;

ANTIBIOTICS; ENCAPSULATION; ETHYLENE; ETHYLENE GLYCOL; FIBROBLASTS; IMPLANTS (SURGICAL); MAMMALS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; RNA; TISSUE;

CELL CULTURE;

COLLAGEN TYPE 1; MACROGOL; MAMMALIAN TARGET OF RAPAMYCIN; POLYETHYLENEIMINE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL LINEAGE; CELL PROLIFERATION; CYTOTOXICITY; DOWN REGULATION; ENCAPSULATION; FEMALE; FOREIGN BODY REACTION; GENE DELIVERY SYSTEM; HYDROGEL; IMPLANT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL PROLIFERATION; COLLAGEN TYPE I; DOWN-REGULATION; DRUG IMPLANTS; FEMALE; FIBROBLASTS; FIBROSIS; FOREIGN-BODY REACTION; HYDROGELS; KINETICS; MICE; MICE, INBRED C57BL; NIH 3T3 CELLS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SOLUBILITY; TOR SERINE-THREONINE KINASES;

EID: 78049478521     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.08.019     Document Type: Article

References (61)

1. Ratner B.D. Reducing capsular thickness and enhancing angiogenesis around implant drug release systems. J. Control Release 2002, 78:211-218.
2. Anderson J.M., Rodriguez A., Chang D.T. Foreign body reaction to biomaterials. Semin. Immunol. 2008, 20:86-100.
3. Song E., Ouyang N., Horbelt M., Antus B., Wang M., Exton M.S. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol. 2000, 204:19-28.
4. Kyriakides T.R., Foster M.J., Keeney G.E., et al. The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. Am. J. Pathol. 2004, 165:2157-2166.
5. Martin P., Leibovich S.J. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol. 2005, 15:599-607.
6. Miller K.M., Anderson J.M. In vitro stimulation of fibroblast activity by factors generated from human monocytes activated by biomedical polymers. J. Biomed. Mater. Res. 1989, 23:911-930.
7. Norton L.W., Koschwanez H.E., Wisniewski N.A., Klitzman B., Reichert W.M. Vascular endothelial growth factor and dexamethasone release from nonfouling sensor coatings affect the foreign body response. J. Biomed. Mater. Res. A 2007, 81:858-869.
8. Blanco E., Weinberg B.D., Stowe N.T., Anderson J.M., Gao J. Local release of dexamethasone from polymer millirods effectively prevents fibrosis after radiofrequency ablation. J. Biomed. Mater. Res. A 2006, 76:174-182.
9. Patil Y., Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int. J. Pharm. 2009, 367:195-203.
10. Dumont F.J., Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 1996, 58:373-395.
11. Law B.K. Rapamycin: an anti-cancer immunosuppressant?. Crit. Rev. Oncol. Hematol. 2005, 56:47-60.
12. Windecker S., Roffi M., Meier B. Sirolimus eluting stent: a new era in interventional cardiology?. Curr. Pharm. Des. 2003, 9:1077-1094.
13. Shegogue D., Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J. Biol. Chem. 2004, 279:23166-23175.
14. Poulalhon N., Farge D., Roos N., et al. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent?. J. Biol. Chem. 2006, 281:33045-33052.
15. Gao X.M., Wong G., Wang B., et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J. Hypertens. 2006, 24:1663-1670.
16. Simler N.R., Howell D.C., Marshall R.P., et al. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur. Respir. J. 2002, 19:1124-1127.
17. Hannon G.J., Rossi J.J. Unlocking the potential of the human genome with RNA interference. Nature 2004, 431:371-378.
18. Jones S.W., Souza P.M., Lindsay M.A. siRNA for gene silencing: a route to drug target discovery. Curr. Opin. pharmacol. 2004, 4:522-527.
19. Aigner A. Delivery systems for the direct aplication of siRNAs to induce RNA interference (RNAi) in vivo. J. Biomed. Biotech. 2006, 2006:1-15.
20. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 2007, 6:443-453.
21. Woodrow K.A., Cu Y., Booth C.J., Saucier-Sawyer J.K., Wood M.J., Saltzman W.M. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater. 2009, 8:526-533.
22. Reich S.J., Fosnot J., Kuroki A., et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 2003, 9:210-216.
23. Takanashi M., Oikawa K., Sudo K., et al. Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. Gene Ther. 2009, 16:982-989.
24. Massaro D., Massaro G.D., Clerch L.B. Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287:L1066-L1070.
25. Thakker D.R., Natt F., Husken D., et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc. Nat. Acad. Sci. U.S.A. 2004, 101:17270-17275.
26. Wu P., Grainger D.W. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 2006, 27:2450-2467.
27. Christie R.J., Findley D.J., Dunfee M., Hansen R.D., Olsen S.C., Grainger D.W. Photopolymerized hydrogel carriers for live vaccine ballistic delivery. Vaccine 2006, 24:1462-1469.
28. van de Wetering P., Metters A.T., Schoenmakers R.G., Hubbell J.A. Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins. J. Control Release 2005, 102:619-627.
29. Metters A., Hubbell J. Network formation and degradation behavior of hydrogels formed by Michael-type addition reactions. Biomacromolecules 2005, 6:290-301.
30. Kyriakides T.R., Zhu Y.H., Yang Z., Huynh G., Bornstein P. Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am. J. Pathol. 2001, 159:1255-1262.
31. Bryers J.D., Jarvis R.A., Lebo J., Prudencio A., Kyriakides T.R., Uhrich K. Biodegradation of poly(anhydride-esters) into non-steroidal anti-inflammatory drugs and their effect on Pseudomonas aeruginosa biofilms in vitro and on the foreign-body response in vivo. Biomaterials 2006, 27:5039-5048.
32. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59:75-86.
33. Almeida R., Allshire R.C. RNA silencing and genome regulation. Trends Cell Biol. 2005, 15:251-258.
34. Soutschek J., Akinc A., Bramlage B., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
35. Sorensen D.R., Leirdal M., Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 2003, 327:761-766.
36. Khan A., Benboubetra M., Sayyed P.Z., et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J. Drug Target 2004, 12:393-404.
37. Sioud M., Sorensen D.R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 2003, 312:1220-1225.
38. Rubinson D.A., Dillon C.P., Kwiatkowski A.V., et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 2003, 33:401-406.
39. Tomar R.S., Matta H., Chaudhary P.M. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 2003, 22:5712-5715.
40. Matta H., Hozayev B., Tomar R., Chugh P., Chaudhary P.M. Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol. Ther. 2003, 2:206-210.
41. SJea Reich Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vision 2004, 9:210-216.
42. Hea Nakamura RNA interference targeting transforming growth factor-β type II receptor suppresses ocular inflammation and fibrosis. Mol. Vis. 2004, 10:703-711.
43. Luo M.C., Zhang D.Q., Ma S.W., et al. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol. Pain 2005, 1:29.
44. Morrissey D.V., Lockridge J.A., Shaw L., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 2005, 23:1002-1007.
45. Schiffelers R.M., Ansari A., Xu J., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32:e149.
46. Park T.G., Jeong J.H., Kim S.W. Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev. 2006, 58:467-486.
47. Wang D.A., Narang A.S., Kotb M., et al. Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules 2002, 3:1197-1207.
48. Jiang G., Park K., Kim J., et al. Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers 2008, 89:635-642.
49. Achenbach T.V., Brunner B., Heermeier K. Oligonucleotide-based knockdown technologies: antisense versus RNA interference. Chembiochem 2003, 4:928-935.
50. Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., Sabatini D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Nat. Acad. Sci. U.S.A. 1998, 95:1432-1437.
51. Wu M.J., Wen M.C., Chiu Y.T., Chiou Y.Y., Shu K.H., Tang M.J. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int. 2006, 69:2029-2036.
52. Neef M., Ledermann M., Saegesser H., Schneider V., Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J. Hepatol. 2006, 45:786-796.
53. Salminen U.S., Maasilta P.K., Taskinen E.I., Alho H.S., Ikonen T.S., Harjula A.L. Prevention of small airway obliteration in a swine heterotopic lung allograft model. J. Heart Lung Transplant. 2000, 19:193-206.
54. Poston R.S., Billingham M., Hoyt E.G., et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999, 100:67-74.
55. Kim K.H., Kim H.C., Hwang M.Y., et al. The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis. Biochem. Biophys. Res. Commun. 2006, 343:1072-1078.
56. Puolakkainen P., Bradshaw A.D., Kyriakides T.R., et al. Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. Am. J. Pathol. 2003, 162:627-635.
57. Qi Z., Atsuchi N., Ooshima A., Takeshita A., Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc. Nat. Acad. Sci. U.S.A. 1999, 96:2345-2349.
58. Kushibiki T., Nagata-Nakajima N., Sugai M., Shimizu A., Tabata Y. Enhanced anti-fibrotic activity of plasmid DNA expressing small interference RNA for TGF-beta type II receptor for a mouse model of obstructive nephropathy by cationized gelatin prepared from different amine compounds. J. Control Release 2006, 110:610-617.
59. Ruiz-de-Erenchun R., Dotor de las Herrerias J., Hontanilla B. Use of the transforming growth factor-beta1 inhibitor peptide in periprosthetic capsular fibrosis: experimental model with tetraglycerol dipalmitate. Plast. Reconstr. Surg. 2005, 116:1370-1378.
60. Kunath K., von Harpe A., Petersen H., et al. The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice. Pharm. Res. 2002, 19:810-817.
61. Haas A. The phagosome: compartment with a license to kill. Traffic 2007, 8:311-330.